CellaVision Beheer

Beheer criteriumcontroles 2/4

De CEO CellaVision is Simon Ostergaard, benoemd in Mar2021, heeft een ambtstermijn van 3.67 jaar. bezit rechtstreeks 0.021% van de aandelen van het bedrijf, ter waarde SEK 1.07M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 3.8 jaar.

Belangrijke informatie

Simon Ostergaard

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	3.7yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	3.8yrs

Recente managementupdates

Recent updates

CEO

Simon Ostergaard (53 yo)

3.7yrs

Tenure

Mr. Simon Ostergaard has been the Chief Executive Officer and President at CellaVision AB (publ) since March 21, 2021. He has broad experience is primarily in CellaVision's adjacent area of pathology and o...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Christer Fahraeus	Founder & Director	no data	SEK 285.00k	6.83% SEK 349.3m
Simon Ostergaard	CEO & President	3.7yrs	geen gegevens	0.021% SEK 1.1m
Magnus Blixt	Chief Financial Officer	11.5yrs	geen gegevens	0.017% SEK 858.0k
Adele Horn	Corporate Communications & Investor Relations Manager	no data	geen gegevens	geen gegevens
Peter Wilson	Vice President of Global Marketing	no data	geen gegevens	0.013% SEK 643.6k
Urban Strindlov	Vice President of Global Sales	2.8yrs	geen gegevens	geen gegevens
Nina Wallander	Vice President of Human Resources	3.8yrs	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0MR5 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Christer Fahraeus	Founder & Director	30.8yrs	SEK 285.00k	6.83% SEK 349.3m
Mikael Worning	Independent Chairman of the Board	4.8yrs	SEK 800.00k	0.0099% SEK 506.0k
Stefan Wolf	Independent Director	6.5yrs	SEK 260.00k	geen gegevens
Ann-Charlotte Jarleryd	Independent Director	2.5yrs	SEK 360.00k	geen gegevens
Kent Strahlen	Independent Employee Representative Director	2.8yrs	geen gegevens	0.0042% SEK 214.4k
Louise Armstrong-Denby	Independent Director	1.5yrs	SEK 130.00k	geen gegevens

3.8yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0MR5 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

CellaVision Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

CellaVision AB (publ), Annual General Meeting, May 06, 2025

Founder & Director recently sold kr27m worth of stock

Founder & Director recently bought kr63k worth of stock

CellaVision AB (publ) Announces the Appointment of Emil Hjalmarsson as Chairman of the Nomination Committee

Founder & Director recently sold kr11m worth of stock

CellaVision Announces Executive Changes

Recent updates

CellaVision AB (publ), Annual General Meeting, May 06, 2025

Now 22% undervalued after recent price drop

Third quarter 2024 earnings released: EPS: kr1.30 (vs kr1.09 in 3Q 2023)

Now 20% undervalued

Founder & Director recently sold kr27m worth of stock

Now 20% undervalued

Second quarter 2024 earnings released: EPS: kr1.62 (vs kr1.46 in 2Q 2023)

New minor risk - Share price stability

Now 20% undervalued

Investor sentiment improves as stock rises 16%

Now 23% undervalued after recent price drop

First quarter 2024 earnings released: EPS: kr1.26 (vs kr0.81 in 1Q 2023)

Now 24% undervalued

Full year 2023 earnings released: EPS: kr5.46 (vs kr4.96 in FY 2022)

Now 22% undervalued

Now 21% undervalued

Dividend of kr2.25 announced

Full year 2023 earnings released: EPS: kr5.46 (vs kr4.96 in FY 2022)

Investor sentiment improves as stock rises 20%

Now 24% undervalued

Now 20% undervalued after recent price drop

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings released: EPS: kr1.09 (vs kr0.43 in 3Q 2022)

CellaVision AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 15%

CellaVision AB (publ) to Report Q3, 2023 Results on Oct 25, 2023

Now 22% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 15%

Second quarter 2023 earnings released: EPS: kr1.46 (vs kr1.56 in 2Q 2022)

Investor sentiment improves as stock rises 16%

CellaVision AB (publ) to Report Q2, 2023 Results on Jul 20, 2023

Investor sentiment deteriorates as stock falls 19%

Cellavision AB (Publ) Approves Dividend, Payable on May 12, 2023

Upcoming dividend of kr2.25 per share at 1.3% yield

Full year 2022 earnings released: EPS: kr4.96 (vs kr5.26 in FY 2021)

Now 22% undervalued after recent price drop

Founder & Director recently bought kr63k worth of stock

Full year 2022 earnings released: EPS: kr4.96 (vs kr5.26 in FY 2021)

Cellavision AB (Publ) Proposes Dividend for 2022

Investor sentiment improves as stock rises 16%

Investor sentiment improved over the past week

CellaVision AB (publ) Announces the Appointment of Emil Hjalmarsson as Chairman of the Nomination Committee

Now 21% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Now 25% undervalued after recent price drop

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Now 21% undervalued after recent price drop

CellaVision® Launches a Complete Workflow Solution for Low-Volume Hematology Laboratories

Second quarter 2022 earnings released: EPS: kr1.56 (vs kr1.30 in 2Q 2021)

Cellavision AB (Publ) Announces Dividend, Payable on 18 May 2022

First quarter 2022 earnings released: EPS: kr1.61 (vs kr1.19 in 1Q 2021)

Upcoming dividend of kr2.00 per share

Full year 2021 earnings released: EPS: kr5.26 (vs kr3.75 in FY 2020)

Cellavision AB (Publ) Proposes Dividend for 2021

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS kr1.09 (vs kr0.56 in 3Q 2020)

Founder & Director recently sold kr11m worth of stock

Second quarter 2021 earnings released: EPS kr1.30 (vs kr1.14 in 2Q 2020)

Independent Chairman of the Board Sören Mellstig has left the company

CellaVision AB (publ) Approves Dividend, Payable on 6 May 2021

Upcoming dividend of kr0.75 per share

Full year 2020 earnings released: EPS kr3.75 (vs kr4.16 in FY 2019)

Revenue misses expectations

Full year 2020 earnings released: EPS kr3.75 (vs kr4.16 in FY 2019)

New 90-day high: kr326

CellaVision Announces Executive Changes